Our intention was not only to ascertain the specificity and prevalence of the two BRCA1/2 mutations (BRCA1, c.5309G>T, and BRCA2, c.1310_1313delAAGA) in the Moroccan Northeastern region, but also to evaluate their role in tumor phenotypic spectrum and disease prognosis, and to establish an adapted and rapid procedure for BRCA1/2 mutations screening among the population of this region for better clinical management of BRCA mutation carriers. This evidence concerns the gene BRCA1 and neoplasm.